Lyra Therapeutics (LYRA) Profit After Tax (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Profit After Tax for 7 consecutive years, with -$7.0 million the latest figure, recorded in Q4 2025.

• Profit After Tax for Q4 2025 came in at -$7.0 million, up 36.61% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28.9 million (up 69.04% YoY), and the FY2025 annual result was -$28.9 million, up 69.05% from the prior year.
• Profit After Tax for Q4 2025 stood at -$7.0 million, down from -$6.0 million in the prior quarter.
• The five-year high for Profit After Tax was -$6.0 million in Q3 2025, with the low at -$48.1 million in Q2 2024.
• A 5-year average of -$14.2 million and a median of -$12.8 million in 2021 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax slumped 208.18% in 2024 and jumped 84.55% in 2025, its largest moves.
• Lyra Therapeutics' Profit After Tax stood at -$13.6 million in 2021, then retreated by 4.5% to -$14.2 million in 2022, then retreated by 6.54% to -$15.2 million in 2023, then rose by 27.65% to -$11.0 million in 2024, then soared by 36.61% to -$7.0 million in 2025.
• The last three Profit After Tax figures came in at -$7.0 million (Q4 2025), -$6.0 million (Q3 2025), and -$7.4 million (Q2 2025), per Business Quant data.